The pluripotency factor NANOG contributes to mesenchymal plasticity and is predictive for outcome in esophageal adenocarcinoma

Background Despite the advent of neoadjuvant chemoradiotherapy (CRT), overall survival rates of esophageal adenocarcinoma (EAC) remain low.

A readily induced mesenchymal transition of EAC cells contributes to resistance to CRT.

Methods In this study, we aimed to chart the heterogeneity in cell state transition after CRT and to identify its underpinnings.

A panel of 12 esophageal cultures were treated with CRT and ranked by their relative epithelial-mesenchymal plasticity.

RNA-sequencing was performed on 100 pre-treatment biopsies.

After RNA-sequencing, Ridge regression analysis was applied to correlate gene expression to ranked plasticity, and models were developed to predict mesenchymal transitions in patients.

Plasticity score predictions of the three highest significant predictive models were projected on the pre-treatment biopsies and related to clinical outcome data.

Motif enrichment analysis of the genes associated with all three models was performed.

Results This study reveals NANOG as the key associated transcription factor predicting mesenchymal plasticity in EAC.

Expression of NANOG in pre-treatment biopsies is highly associated with poor response to neoadjuvant chemoradiation, the occurrence of recurrences, and median overall survival difference in EAC patients (>48 months).

Perturbation of NANOG reduces plasticity and resensitizes cell lines, organoid cultures, and patient-derived in vivo grafts.

Conclusions In conclusion, NANOG is a key transcription factor in mesenchymal plasticity in EAC and a promising predictive marker for outcome.

Esophageal cancer is the sixth most common cause of cancer-related death worldwide.

Although chemotherapy combined with radiotherapy (chemoradiotherapy) followed by surgery has improved survival, tumor recurrence and metastatic disease (that has spread to other parts of the body) are often observed after several months.

In this study, we assessed the effect of chemoradiotherapy on esophageal cells in the lab to predict the effect in patients with esophageal cancer.

To investigate this, genes were assessed from 12 different cell lines and 100 patient tissues.

We revealed that levels of one of the genes, NANOG , associates with poor response in patients.

NANOG could be a promising marker to predict outcome in patients with esophageal cancer.

This knowledge might help clinicians to treat patients with esophageal cancer appropriately, or may lead to new or optimized treatments.

Van der Zalm et al. apply Ridge regression analysis to RNA-seq data from esophageal cancer samples to predict mesenchymal transitions occurring in patients.

Expression of NANOG in pre-treatment biopsies is associated with poor response to neoadjuvant chemoradiation, recurrence, and median overall survival in patients with esophageal adenocarcinoma.